Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 526 Commerce Circle, Ste. #120 MESQUITE NV 89027 |
Tel: | N/A |
Website: | https://uhpcorp.com |
IR: | See website |
Key People | ||
Brian Thom Chief Executive Officer, Director | Kristofer Heaton Principal Financial Officer, Vice President - Finance | Louis Schiliro Treasurer, Company Secretary |
Business Overview |
United Health Products, Inc. develops, manufactures, and markets a hemostatic gauze for the healthcare and wound care sectors. Its gauze product, HemoStyp, is derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. HemoStyp hemostatic gauze is a flexible, silk-like material that is applied by placing the gauze onto the bleeding tissue. The supple material can be easily folded and manipulated as needed to fit the size of the wound or incision. In surface bleeding and surgical situations, the product quickly converts to a translucent gel that allows the physician or surgeon to monitor the coagulation process. In superficial bleeding situations, HemoStyp can be bonded to an adhesive plastic bandage or integrated into a traditional gauze component to address a range of needs, including traumatic bleeding injuries and prolonged bleeding following hemodialysis. Its customer base includes hospitals, surgery centers, clinics and others. |
Financial Overview |
For the fiscal year ended 31 December 2023, United Health Products Inc revenues decreased from $38K to $0K. Net loss increased 55% to $2.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other Income decrease from $1.4M (income) to $0K, Interest Expense increase from $17K to $41K (expense). |
Employees: | 6 as of Apr 1, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $48.15M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$2.42M as of Dec 31, 2023 |
Net annual income (TTM): | -$2.62M as of Dec 31, 2023 |
Free cash flow (TTM): | -$2.20M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $0.61M as of Dec 31, 2023 |
Shares outstanding: | 246,833,222 as of Apr 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |